Company profile
Alpha Teknova, Inc.
NASDAQ: TKNO · Healthcare · Drug Manufacturers - Specialty & Generic
#464 of 1,418 Healthcare companies by revenue52nd-percentile growth
EA Score
58CFH 66DQ 46GM 58SS 54
v0.1 · 65/100 weight · provisional
↑ growth stability, Altman-Z · ↓ listing tenure, disclosure history
Methodology →Revenue TTM
$41.8M
Rev growth YoY (TTM)
+9.3%
Net income (FY)
-$17.3M
Employees
158
as of 2026-08-13
Market cap
$396.2M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$40.5M$40.5M2025
Net income-$17.3M-$17.3M2025
Operating income-$17.0M-$17.0M2025
Total assets$103.6M$103.6M2025
Liabilities$34.8M$34.8M2025
Equity$68.8M$68.8M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Lab Essentials77%
Clinical Solutions19%
Other Product5%
By geography
UNITED STATES94%
Non-US6%
The read
What is Alpha Teknova, Inc.’s revenue?
Alpha Teknova, Inc. booked $40.5M in FY2025 revenue, growing 7.4% year over year — about the middle of the pack among Healthcare companies we track, at a -42.6% net margin.
Peers · Healthcare
Equillium, Inc.44DMyomo, Inc.53DEditas Medicine, Inc.45DVoyager Therapeutics, Inc.53DValeo Pharma Inc.——Enveric Biosciences, Inc.31DKey facts
CEOStephen Gunstream
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersHollister, CA
ExchangeNASDAQ: TKNO
Employees158
IPO date2021-06-25
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.